arrow_back Back to App

Securing Drug Supply: Boosting US Manufacturing and Transparency.

This Act aims to secure the supply of critical medicines in the US by reducing reliance on foreign manufacturers. It mandates the creation of a list of drugs essential for public health and national security and authorizes $5 billion for contracts with US companies to build domestic capacity for manufacturing drug ingredients. Citizens can expect greater stability in access to necessary medications and increased price transparency for drugs produced under these contracts.
Key points
A confidential list of drugs critical to public health and national security will be created to focus production efforts.
$5 billion is authorized for contracts with US companies to increase domestic manufacturing of critical drug ingredients, reducing import dependency.
Contracted companies must maintain drug reserves and commit to selling products at public, "fair and reasonable prices," protecting patients from excessive costs.
Starting in 2029, federal agencies must prioritize purchasing critical drugs wholly manufactured in the United States.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_5638
Sponsor: Sen. Warren, Elizabeth [D-MA]
Process start date: 2024-12-19
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Supply Chain Defense and Enhancement Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_5638.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-12-19.

What are the main provisions?

Key points include:

  • A confidential list of drugs critical to public health and national security will be created to focus production efforts.
  • $5 billion is authorized for contracts with US companies to increase domestic manufacturing of critical drug ingredients, reducing import dependency.
  • Contracted companies must maintain drug reserves and commit to selling products at public, "fair and reasonable prices," protecting patients from excessive costs.
  • Starting in 2029, federal agencies must prioritize purchasing critical drugs wholly manufactured in the United States.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Warren, Elizabeth [D-MA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Security Economy